Oral mucositis (moderate to severe) · Adults with solid cancers receiving fluorouracil (5FU) and leucovorin
It is very uncertain whether oral cryotherapy for 30 minutes changes oral mucositis (moderate to severe) compared with oral cryotherapy for 60 minutes (very low certainty).
1 finding from 1 review
Oral mucositis (severe) · Adults with solid cancers receiving fluorouracil (5FU) and leucovorin
It is very uncertain whether oral cryotherapy for 30 minutes changes oral mucositis (severe) compared with oral cryotherapy for 60 minutes (very low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Adults with solid cancers receiving fluorouracil (5FU) and leucovorin
It is very uncertain whether oral cryotherapy for 30 minutes changes oral mucositis (any severity) compared with oral cryotherapy for 60 minutes (very low certainty).
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3 (NSAIDs vs placebo), Cancer development: SoF cell 'Not measured'. Effects text: cancer development was among outcomes in Papadimitrakopoulou 2008 (celecoxib) but did not occur in either arm, probably because of…
1 study
GRADE not reported
Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Oral mucositis (severe) · All patients with cancer who are receiving treatment
Oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… probably leads to lower oral mucositis (severe) compared with control (no treatment or standard/usual oral care, e.g. saline rinse) (moderate certainty).
3 findings from 1 review
RR 0.38 [0.20, 0.72]
5 studies · 270 participants
Moderate
RR 0.88 [0.61, 1.25]
1 study · 122 participants
Very low
RR 0.40 [0.27, 0.61]
5 studies · 444 participants
Moderate
Oral mucositis (mean severity on WHO 0 to 4 scale) · All patients with cancer who are receiving treatment
It is very uncertain whether oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… changes oral mucositis (mean severity on WHO 0 to 4 scale) compared with control (no treatment or standard/usual oral care, e.g. saline rinse) (very low certainty).
1 finding from 1 review
Oral pain · All patients with cancer who are receiving treatment
3 findings from 1 review
Oral pain was assessed in this subgroup but the study (Kakoei 2013) did not report details of the scale used, so the data could not be used (no usable estimate).
1 study
GRADE not reported
MD -1.93 [-2.37, -1.49]
1 study · 80 participants
Very low
MD -1.5 [-2.11, -0.89]
2 studies · 85 participants
Low
Oral mucositis (any severity) · All patients with cancer who are receiving treatment
Oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… showed no clear difference in oral mucositis (any severity) compared with control (no treatment or standard/usual oral care, e.g. saline rinse) (low certainty).
3 findings from 1 review
RR 0.59 [0.35, 1.01]
5 studies · 270 participants
Low
RR 0.61 [0.52, 0.72]
5 studies · 444 participants
Moderate
RR 0.98 [0.90, 1.07]
1 study · 122 participants
Very low
Oral mucositis (moderate to severe) · All patients with cancer who are receiving treatment
Oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… showed no clear difference in oral mucositis (moderate to severe) compared with control (no treatment or standard/usual oral care, e.g. saline rinse) (low certainty).
3 findings from 1 review
RR 0.43 [0.17, 1.09]
5 studies · 270 participants
Low
RR 1.01 [0.85, 1.20]
1 study · 122 participants
Very low
RR 0.52 [0.41, 0.65]
5 studies · 444 participants
Moderate
Number of days unable to take medicine orally · All patients with cancer who are receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Oral care protocol showed no clear difference in oral mucositis (moderate to severe) compared with no treatment/usual care; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Oral care protocol showed no clear difference in oral mucositis (severe) compared with no treatment/usual care; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Oral care protocol led to lower oral mucositis (any severity) compared with no treatment/usual care; GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.
1 finding from 1 review
Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported
Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Oral mucositis (severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
2 findings from 1 review